Regeneron Pharmaceuticals (REGN) Retained Earnings (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Retained Earnings of $37.6 billion for Q2 2026, up 11.7% year-over-year from $33.7 billion in Q2 2025, and up 3.29% quarter-over-quarter from $36.4 billion in Q1 2026.
Regeneron Pharmaceuticals (REGN) Retained Earnings (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Retained Earnings history runs 18 years deep, the most recent figure standing at $37.6 billion for Q2 2026.
- In Q2 2026, Retained Earnings rose 11.7% year-over-year to $37.6 billion; the TTM figure through Jun 2026 stood at $37.6 billion (up 11.7% YoY), while the FY2025 annual figure was $35.8 billion, up 13.02% from the prior year.
- Retained Earnings for Q2 2026 stood at $37.6 billion, up from $36.4 billion in the prior quarter.
- The five-year high for Retained Earnings was $37.6 billion in Q2 2026, with the low at $19.9 billion in Q1 2022.
- The 5-year median for Retained Earnings is $28.7 billion (2024), against an average of $28.9 billion.
- The sharpest annual moves came in 2022 and 2026: Retained Earnings jumped 66.07% in 2022, then advanced 11.7% in 2026.
- Regeneron Pharmaceuticals' Retained Earnings stood at $23.3 billion in 2022, then gained by 16.96% to $27.3 billion in 2023, then grew by 16.19% to $31.7 billion in 2024, then increased by 13.02% to $35.8 billion in 2025, then advanced by 5.1% to $37.6 billion in 2026.
- Business Quant data shows REGN's Retained Earnings at $37.6 billion in Q2 2026, $36.4 billion in Q1 2026, and $35.8 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 5.13 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.62 Bn |
| Mar 31, 2026 | 11.90 Mn |
| Dec 31, 2025 | 35.80 Bn |
| Sep 30, 2025 | 69.00 Mn |
| Jun 30, 2025 | 52.50 Mn |
| Mar 31, 2025 | 29.10 Mn |
| Dec 31, 2024 | 12.86 Bn |
| Sep 30, 2024 | 60.20 Mn |
| Jun 30, 2024 | 12.32 Bn |
| Mar 31, 2024 | 11.94 Bn |
| Dec 31, 2023 | 27.26 Bn |
| Sep 30, 2023 | 26.10 Bn |
| Jun 30, 2023 | -197.70 Mn |
| Mar 31, 2023 | 24.12 Bn |
| Dec 31, 2022 | 23.31 Bn |
| Sep 30, 2022 | -275.10 Mn |
| Jun 30, 2022 | 9.12 Bn |
| Mar 31, 2022 | 19.94 Bn |
| Dec 31, 2021 | 8.09 Bn |
| Sep 30, 2021 | 16.74 Bn |